First author, publication year | Type | No of patients on active therapy (n = 121) | Method quality | Treatment period (weeks) | Mean baseline pain (mm VAS) | Best mean difference (95% CI) of change over placebo (mm VAS) | Outcome assessment timepoints (weeks, best time point used in bold) |
---|---|---|---|---|---|---|---|
Sangdee-03 | Maximal tolerable intensity | 48 | 5 | 4 | 66.9 | 25.0 (15.2 to 34.8) | 4, 8, 12 |
Vas-04 | Maximal tolerable intensity | 48 | 4 | 12 | 58.9 | 25.0 (13.4 to 36.6) | 12 |
Yurtkuran-99 | Maximal tolerable intensity | 25 | 3 | 2 | - | 20.0 (14.1 to 25.9) | 2 |
12 weeks Global improved | Â | 48 | Â | Â | Â | 2.1 (1.1 to 4.1) Relative Risk | Â |
Best within 4 weeks |  | 73 | 4* |  | 62.9†| 21.3†(16.3 to 26.3) | 3* |
Total |  | 121 | 4* |  | 62.9†| 21.9†(17.3 to 25.3) | 3* |